AVENUE THERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.4M | $0 |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $1.0M | $6.6M |
| SG&A Expense | $3.7M | $4.6M |
| Operating Income | $-3.1M | $-11.3M |
| Operating Margin | -219.6% | — |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | $2.0K | $0 |
| Net Income | $-2.9M | $-11.7M |
| Net Margin | -207.2% | — |
| EPS (Basic) | $-0.93 | $-7.90 |
| EPS (Diluted) | — | — |
| Shares Outstanding (Basic) | 3.1M | 2.6M |
| Shares Outstanding (Diluted) | 3.1M | 2.6M |
| Dividends Per Share | — | — |